NO ASSOCIATION BETWEEN C-MYC AMPLIFICATION AND TP53 MUTATION IN SARCOMA TUMORIGENESIS

被引:12
|
作者
CASTRESANA, JS
BARRIOS, C
GOMEZ, L
KREICBERGS, A
机构
[1] KAROLINSKA HOSP & INST,DEPT TUMOR PATHOL,S-10401 STOCKHOLM,SWEDEN
[2] KAROLINSKA HOSP & INST,DEPT ORTHOPED,S-10401 STOCKHOLM,SWEDEN
[3] MASSACHUSETTS GEN HOSP,MOLEC NEUROONCOL LAB,BOSTON,MA 02129
[4] MASSACHUSETTS GEN HOSP,NEUROSURG SERV,BOSTON,MA 02129
[5] HARVARD UNIV,SCH MED,BOSTON,MA 02129
关键词
D O I
10.1016/0165-4608(94)90070-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oncogenes and tumor suppressor genes coparticipate in sarcoma tumorigenesis. We tested 43 sarcomas for c-myc amplification by Southern blot and molecular hybridization techniques and TP53 mutations by the polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and direct sequencing of the PCR products. We found eight tumors with c-myc amplification and five different tumors with TP53 mutations but no tumors harbor both c-myc and TP53 alterations. We suggest that c-myc amplification and TP53 mutations do not seem to coparticipate in the tumorigenesis of sarcomas.
引用
收藏
页码:47 / 49
页数:3
相关论文
共 50 条
  • [1] TP53, β-Catenin and c-myc/N-myc status in embryonal tumours with ependymoblastic rosettes
    Gessi, M.
    zur Muehlen, A.
    Lauriola, L.
    Gardiman, M. P.
    Giangaspero, F.
    Pietsch, T.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2011, 37 (04) : 406 - 413
  • [2] TP53 AND C-MYC CO-ALTERATIONS - A HALLMARK OF ORAL CANCER PROGRESSION
    Tanic, Nasta
    Milasin, Jelena
    Dramicanin, Tatjana
    Boskovic, Maja
    Vukadinovic, Miroslav
    Milosevic, Verica
    Tanic, Nikola
    JOURNAL OF MEDICAL BIOCHEMISTRY, 2013, 32 (04) : 380 - 388
  • [3] Contribution of germline TP53 mutation in sporadic sarcoma cases
    Haque, Md. M.
    Puri, A.
    Sarin, R.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : S52 - S52
  • [4] Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma
    Ortiz-Cuaran, Sandra
    Cox, David
    Villar, Stephanie
    Friesen, Marlin D.
    Durand, Geoffroy
    Chabrier, Amelie
    Khuhaprema, Thiravud
    Sangrajrang, Suleeporn
    Ognjanovic, Simona
    Groopman, John D.
    Hainaut, Pierre
    Le Calvez-Kelm, Florence
    GENES CHROMOSOMES & CANCER, 2013, 52 (10): : 912 - 919
  • [5] Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification
    Lin, Xiaoyi
    Lin, Xin
    Guo, Lijuan
    Wang, Yulei
    Zhang, Guochun
    THORACIC CANCER, 2022, 13 (24) : 3441 - 3450
  • [6] Co-occurrence of MYC amplification and TP53 mutations in human cancer
    Ulz, Peter
    Heitzer, Ellen
    Speicher, Michael R.
    NATURE GENETICS, 2016, 48 (02) : 104 - 106
  • [7] Co-occurrence of MYC amplification and TP53 mutations in human cancer
    Peter Ulz
    Ellen Heitzer
    Michael R Speicher
    Nature Genetics, 2016, 48 : 104 - 106
  • [8] Mutation and function of TP53
    Milner, J
    BRAIN PATHOLOGY, 2000, 10 (04) : 504 - 504
  • [9] The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
    Leroy, Bernard
    Fournier, Jean Louis
    Ishioka, Chikashi
    Monti, Paola
    Inga, Alberto
    Fronza, Gilberto
    Soussi, Thierry
    NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D962 - D969
  • [10] Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis?
    RoyBurman, P
    Zheng, JP
    Miller, GJ
    MOLECULAR MEDICINE TODAY, 1997, 3 (11): : 476 - 482